Clearing the TRAIL for Cancer Therapy

59Citations
Citations of this article
28Readers
Mendeley users who have this article in their library.

Abstract

The death receptor ligand TRAIL has shown remarkable promise as an anticancer agent. However, TRAIL signaling also activates NF-κB, which induces the antiapoptotic regulators Mcl-1 and cIAP2, thus compromising its efficacy. In this issue of Cancer Cell, El-Deiry and colleagues explore pathways that disrupt TRAIL-induced survival signaling and show that the Myc oncoprotein and the Raf kinase inhibitor Sorafenib sensitize otherwise TRAIL-resistant colon cancer cells by effectively reducing NF-κB-mediated transcription of Mcl-1. These findings suggest that combining TRAIL with agents that disrupt NF-κB regulation or binding or those that directly destabilize or disable Mcl-1 will have therapeutic benefit. © 2007 Elsevier Inc. All rights reserved.

Cite

CITATION STYLE

APA

Hall, M. A., & Cleveland, J. L. (2007, July 10). Clearing the TRAIL for Cancer Therapy. Cancer Cell. https://doi.org/10.1016/j.ccr.2007.06.011

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free